ACCC green-lights pharma merger subject to divestment undertakings

The ACCC has announced that it will not oppose Mylan NV’s proposed merger with Mfizer’s Upjohn Inc division. This follows Mylan and Upjohn’s offer to provide a court-enforceable undertaking to divest three off-patent branded pharmaceuticals. Aspen has been approved by the ACCC up front as the buyer.

See ACCC, ‘Divestments overcome strong competition concerns with pharmaceutical merger’ (Media Release, 10 September 2020)

View merger register.